Full Text View
Tabular View
Study Results
Related Studies
Safety Study of Ethinylestradiol/Drospirenone in Dysmenorrhea
This study has been completed.
Study NCT00461305   Information provided by Bayer

First Received on April 17, 2007.   Last Updated on January 22, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Dysmenorrhea
More general conditions related to this trial
Menstruation Disturbances
Pain
Pathologic Processes
Pelvic Pain
Signs and Symptoms
Interventions listed in this trial
DRSP 3 mg/EE 20 µg (13 cycles)
DRSP 3 mg/EE 30 µg (6 cycles)
Additional drug interventions recognized in this trial
Drospirenone
Drospirenone and ethinyl estradiol combination
Ethinyl Estradiol
More general drug interventions related to this trial
Aldosterone Antagonists
Estrogens
Hormone Antagonists
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses
Sponsors listed in this trial
Bayer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services